These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 16638639)

  • 21. [Selection and pharmacological characterisation of Procoralan, a selective inhibitor of the pacemaker If current].
    Vilaine JP
    Therapie; 2004; 59(5):495-505. PubMed ID: 15648301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The funny current: cellular basis for the control of heart rate.
    DiFrancesco D; Borer JS
    Drugs; 2007; 67 Suppl 2():15-24. PubMed ID: 17999560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart rate reduction by pharmacological If current inhibition.
    Cargnoni A; Ceconi C; Stavroula G; Ferrari R
    Adv Cardiol; 2006; 43():31-44. PubMed ID: 16936470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK; Gray D; Purcell H
    Adv Ther; 2009 Feb; 26(2):127-37. PubMed ID: 19259630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
    Camici PG; Gloekler S; Levy BI; Skalidis E; Tagliamonte E; Vardas P; Heusch G
    Int J Cardiol; 2016 Jul; 215():1-6. PubMed ID: 27104917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivabradine: beyond heart rate control.
    Riccioni G; Vitulano N; D'Orazio N
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
    Heusch G; Kleinbongard P
    Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ivabradine: the hope for a good treatment of ischemic heart disease.
    Riccioni G
    Curr Med Chem; 2013; 20(14):1817-23. PubMed ID: 23394554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective and specific I(f) inhibition: new perspectives for the treatment of stable angina.
    Fox K
    Expert Opin Pharmacother; 2006 Jun; 7(9):1211-20. PubMed ID: 16732707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. I(f) inhibition in cardiovascular diseases.
    Thollon C; Vilaine JP
    Adv Pharmacol; 2010; 59():53-92. PubMed ID: 20933199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
    Filipovský J
    Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J
    Methods Find Exp Clin Pharmacol; 2008 Oct; 30(8):633-41. PubMed ID: 19088948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. I f inhibition with ivabradine : electrophysiological effects and safety.
    Savelieva I; Camm AJ
    Drug Saf; 2008; 31(2):95-107. PubMed ID: 18217787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G
    Adv Ther; 2010 Mar; 27(3):160-7. PubMed ID: 20419486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease.
    Cacciapuoti F
    Ther Adv Cardiovasc Dis; 2016 Apr; 10(2):98-102. PubMed ID: 26944071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.